Tirzepatide vs Retatrutide: Comparing the Metabolic Peptides
The core difference between tirzepatide and retatrutide is the number of receptors they target: tirzepatide is a dual agonist acting on GLP-1 and GIP receptors, while retatrutide is a triple agonist adding glucagon-receptor activity on top of GLP-1 and GIP. Retatrutide is therefore studied as a next-generation, broader-acting metabolic research compound.
Tirzepatide and retatrutide are two of the most-studied incretin research peptides. They are frequently compared because both act on metabolic pathways — but retatrutide targets an additional receptor.
What is the difference between tirzepatide and retatrutide?
Tirzepatide is a dual incretin receptor agonist, activating both the GLP-1 and GIP receptors. Retatrutide is a triple agonist — it activates GLP-1, GIP, and additionally the glucagon receptor. That third glucagon-receptor action is the defining difference and is why retatrutide is described as a next-generation metabolic compound in research.
Side-by-side comparison
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptor targets | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Agonist type | Dual | Triple |
| Research focus | Metabolic / glucose regulation | Broader metabolic / energy expenditure |
| Generation | Established incretin research | Next-generation research compound |
Why the extra receptor matters
In preclinical research, glucagon-receptor activity is associated with energy expenditure and hepatic glucose handling. Adding it to the GLP-1/GIP combination is why retatrutide is studied for potentially broader metabolic effects than dual agonists.
Handling
Both are lyophilized powders requiring reconstitution with bacteriostatic water.
Read: How to reconstitute peptides →Key takeaways
- Tirzepatide: dual agonist — GLP-1 and GIP receptors.
- Retatrutide: triple agonist — GLP-1, GIP, and glucagon receptors.
- Retatrutide adds a glucagon-receptor component tirzepatide does not have.
- Both are studied in preclinical metabolic and energy-balance research.